{"@id":"https://bioecon.ru/technology/o-glcnacase-inhibitors/","@type":"Technology","cluster":"therapeutics-platforms","formats":{"html":"https://bioecon.ru/technology/o-glcnacase-inhibitors/","json":"https://bioecon.ru/api/v1/technology/o-glcnacase-inhibitors/index.json"},"id":"o-glcnacase-inhibitors","industries":["pharma","biomanufacturing"],"lang":"ru","links":{"industries":["https://bioecon.ru/industries/pharma/","https://bioecon.ru/industries/biomanufacturing/"],"suppliers":["https://bioecon.ru/companies/novartis/","https://bioecon.ru/companies/vci-technology-sdn-bhd/","https://bioecon.ru/companies/atomwise/","https://bioecon.ru/companies/fytofend/","https://bioecon.ru/companies/brain-biotech/","https://bioecon.ru/companies/evogene/","https://bioecon.ru/companies/tilak-paints/","https://bioecon.ru/companies/zero-cow-factory/","https://bioecon.ru/companies/insilico-medicine/","https://bioecon.ru/companies/microbika/","https://bioecon.ru/companies/shenzhen-siyomicro-bio-tech/"]},"maturity":7,"name":"Ингибиторы O-GlcNAc-гидролазы (OGA)","regions":["ch","eu","us","cn"],"risk":"medium","section":"technology","sector":"health-biomedicine","sources":[{"date":"2026-11-22","entity":"Swiss Biotech Directory 2026","kind":"vendor","urls":["https://www.swissbiotech.org/directory/"]}],"stages":[{"n":1,"title":"Дизайн ингибиторов переходного состояния"},{"n":2,"title":"Преодоление барьера мозг-кровь"},{"n":3,"title":"Блокирование агрегации тау-белка"},{"n":4,"title":"ПЭТ-биомаркеры в клинике"}],"summary":"Проникающие в мозг низкомолекулярные ингибиторы O-GlcNAc-гидролазы (OGA), увеличивающие защитное гликозилирование белков тау и альфа-синуклеина и предотвращающие гибель нейронов.","url":"/technology/o-glcnacase-inhibitors/","verified":"2026-11-22"}